The publication of this infographic was sponsored and funded by BioMarin Pharmaceutical Inc. This content is intended for healthcare professionals only.
Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page, and the bottom of this infographic.
This infographic details the presentation, progression, and treatment of neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a progressive neurodegenerative disease in which a genetic mutation causes a lack of functional TPP1 enzyme. It describes the primary Phase I/II study and open-label extension, analysing the safety and efficacy of cerliponase alfa for CLN2 treatment.
Please refer to full prescribing information before using BRINEURA.
Prescribing information and a full list of adverse events can be accessed here. Please access your local authorities prescribing information.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
| Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. Healthcare professionals in the UK, can report via the Yellow Card Scheme linked here or search for MHRA Yellow Card in the Google Play or Apple App Store. |
